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ahis review summarizes important advances in athero-
hrombosis within the last year, with a particular emphasis
n risk factors and markers of disease, progress in imaging,
nd advances in therapy. Major journals in cardiology and
nternal medicine published in English and in PubMed
ere carefully searched for relevant studies in all 3 catego-
ies. Representative articles were selected on the basis of
linical relevance and scientific merit.
arkers of Cardiovascular Risk and/or Disease
raditional risk factors. Early detection and risk stratifi-
ation continued to be some of the main focuses of
therothrombosis research. In parallel with the quest for
ovel disease markers, the substantial impact of conven-
ional risk factors was emphasized in several reports. Car-
iovascular disease has become the global leading cause of
eath worldwide (Fig. 1). Furthermore, arterial hyperten-
ion, hypercholesterolemia, and smoking lead the list of risk
actors associated with mortality (1). A large international
egistry showed that the risk profile in atherothrombotic
atients is similar throughout the world, although risk
actors are largely undertreated and undercontrolled (2).
he growing impact of obesity as an independent risk factor
eceived particular attention. Large, prospective studies
howed that not only obesity but also excess weight is
ndependently associated with increased mortality in both
en and women, and across various age and ethnic groups
3). Emphasizing the difference between adipose and lean
ass, the waist-to-hip ratio was a stronger independent
arker of risk of myocardial infarction than the body mass
ndex in a study of 27,000 patients worldwide (4). There was
lso increasing evidence of the importance of air pollution at
ommon levels of exposure as a novel risk factor, associated
ith increased vascular inflammation and atherogenesis in
polipoprotein E knockout mice (5).
hysical markers. An abnormally low (1.1) or high
1.4) ankle-brachial index as an indicator of peripheral
isease was shown to predict increased future cardiovascular
vents in the general population after adjustment for poten-
ial confounders (6). In addition, prospective evidence
rom The Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josee and
enry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine,p
ew York, New York.
Manuscript received November 10, 2006; accepted November 21, 2006.ccumulated regarding the prognostic significance of mea-
urements of arterial stiffness, specifically aortic pulse wave
elocity (7).
erum biomarkers. The importance of the link between
nflammation and atherothrombosis was reiterated by the
argest published series so far evaluating histologic features
f symptomatic carotid plaques, in which inflammation
howed the strongest association with plaque instability (8).
he role and implications of C-reactive protein (CRP)
ontinued to be a major focus of attention. Data from the
allas Heart Study showed no association of CRP concen-
rations with the burden of subclinical atherosclerosis,
uggesting that they reflect different aspects of the disease
9). To understand the sources of serum CRP level variabil-
ty, a substudy of the Framingham offspring cohort reported
hat 12 clinical variables (that spanned conventional markers
f risk) explained 26% of CRP concentration variability (the
ody mass index alone explained 15%). In addition, a
ingle-nucleotide polymorphism with independent associa-
ion with CRP levels was identified, although it explained
nly 1.4% of total variability (10). Whether CRP represents
bystander or a contributor to disease progression contin-
ed to be a matter of debate. Newly described potentially
roatherogenic actions of CRP included induction of matrix
etalloproteinases-1 and -10 secretion (11), and the acti-
ation of nuclear factor B, a central mediator in athero-
enesis (12). However, a study in3,000 women evaluating
he distribution of CRP haplotypes and metabolic syndrome
henotype did not suggest a causal role of CRP within this
linical context (13).
Another serum biomarker that gained significant atten-
ion was adiponectin, an adipocyte-derived peptide with
nti-inflammatory and antiatherogenic properties. Al-
hough decreased serum concentrations have been advo-
ated as a strong predictor of incident coronary heart
isease, a large prospective study with a concomitant meta-
nalysis of prior prospective investigations showed a modest,
onsignificant association (14). Regarding hemostatic
arkers, elevated levels of fibrinogen, plasminogen activator
nhibitor-1, and D-dimer were independently associated
ith increased incidence of cardiovascular events, whereas
actor VIIc showed an inverse association (15). The inter-
ction between inflammation and coagulability was evalu-
ted measuring platelet gene expression of myeloid-related
rotein 14, a chemoattractant that regulates leukocyte ad-
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April 24, 2007:1740–9 Year in Atherothrombosisesion. In comparison with subjects with stable disease,
atients with acute myocardial infarction showed higher
lasmatic concentrations of myeloid-related protein 14.
ost importantly, serum levels prospectively predicted car-
iovascular events above and beyond CRP and conventional
isk factors (16).
Substantial evidence accumulated on the ability of brain
atriuretic peptide (BNP) to predict future cardiovascular
vents in several patient subgroups. Results from the
therogene Study confirmed markedly increased cardiovas-
ular risk in patients with stable angina and elevated plasma
NP levels after adjustment for conventional risk factors,
RP, multivessel disease, and left ventricular ejection frac-
ion (17). In addition, persistent BNP elevation may iden-
ify those individuals remaining at higher risk after an acute
vent (18). Troponin I was shown to predict mortality and
ncident coronary disease in older men after adjusting for
onventional risk factors, suggesting that subclinical cardiac
amage strongly influences prognosis (19). A substudy of
he OPUS–TIMI (Orbofiban in Patients with Unstable
oronary Syndromes–Thrombolysis In Myocardial Infarc-
ion) 16 trial evaluated the prognostic significance of heart-
ype fatty acid binding protein, another protein released
rom the myocardium in response to injury. During a
0-month follow-up after an acute coronary syndrome,
ubjects with elevated concentrations were more likely to
uffer death, myocardial infarction, or congestive heart
ailure, even after accounting for clinical variables, troponin
, or BNP (Fig. 2) (20).
linical implications of serum biomarkers versus tradi-
ional risk factors. The practical value of measuring indi-
idual biomarkers was questioned in a report from the
Figure 1 Worldwide Causes of
Death Secondary to Chronic Diseases
Reprinted with permission from Fuster V, Voute J. MDGs: chronic diseases are
not on the agenda. Lancet 2005;366:1512–14. AIDS  acquired immunodefi-
ciency syndrome; HIV  human immunodeficiency virus.RIC (Atherosclerosis Risk in Communities) study, inhich 19 novel markers of inflammation, thrombogenicity,
xidative stress, endothelial function, or chronic infection
ere quantified in 15,792 individuals. The ability to predict
he 5-year incidence of coronary disease by conventional risk
actors was insignificantly or only marginally improved by
ovel biomarkers, including CRP (21). Similar results were
ommunicated in the setting of secondary prevention in a
ubset of 3,199 patients enrolled in the HOPE (Heart
utcomes Prevention Evaluation) study. In another multi-
ariate model that included conventional prognosticators,
everal biomarkers (N-terminal pro-BNP, soluble intercel-
ular adhesion molecule 1, microalbuminuria, soluble
nterleukin-1 receptor antagonist, and fibrinogen) remained
ignificantly associated with the risk of infarction, stroke, or
ardiovascular death. However, only the addition of
-terminal pro-BNP provided incremental predictive accu-
acy to the model, even when combinations of multiple
iomarkers were evaluated (22). Although these results do
ot necessarily invalidate the quantification of serum mark-
rs for the prediction of specific outcomes or in selected
atient subsets, they again emphasized the importance of
onventional, modifiable risk factors.
ndothelial repair and progenitor cells. Endothelial pro-
enitor cells (EPCs) derive from different organs (predom-
nantly the bone marrow) and play an important role in
ndogenous repair of endothelium damaged by risk factors
r other mechanisms. Low plasmatic levels of CD34
PCs were associated with various cardiovascular risk fac-
ors (including the metabolic syndrome) and were indepen-
ent predictors of high Framingham risk scores (23). Some
tudies found an inverse correlation between EPC levels and
therosclerosis extent (24). These results suggest that con-
inued vascular damage associated with insufficient repara-
ive ability might result in increased atherosclerosis. None-
heless, one study paradoxically reported an independent
ssociation between elevated EPC number and angio-
Figure 2 Predictive Value of H-FABP
After an Acute Coronary Syndrome
Rates of death, myocardial infarction (MI), or congestive heart failure (CHF)
stratified by baseline concentration of brain natriuretic peptide (BNP), tropo-
nin I (Tn), or heart-type fatty acid binding protein (H-FABP) in the OPUS-TIMI 16
study. BNP   BNP 80 pg/ml; Tn   troponin I 1.5 ng/ml. Reproduced
with permission from O’Donoghue et al. (20).
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Year in Atherothrombosis April 24, 2007:1740–9raphic coronary disease severity, with the highest numbers
btained in patients requiring revascularization (25). Hence,
ur understanding of the interaction between EPC levels
nd disease state is still evolving and requires additional
esearch. This controversy was elegantly discussed by Leor
ndMarber (26), highlighting the potential shortcomings of
ttempting clinical studies before understanding the patho-
hysiological role of endogenous EPCs.
enetic markers. Novel genetic polymorphisms associated
ith increased risk included a variant of the vitamin K
poxide reductase gene, involved in the synthesis of coagu-
ation factors, or endothelial nitric oxide synthase, required
or the generation of the protective molecule nitric oxide
27,28). Nonetheless, the difficulty of identifying clinically
eaningful genetic polymorphisms was highlighted in a
arge meta-analysis of 191 studies (n 150,000) studying 7
emostatic genes. Only 2 variants of the factor V and
rothrombin genes showed significant, although weak, as-
ociations with coronary disease (29). Another polymor-
hism of growing interest is related to the haptoglobin
rotein, a defensive mechanism responsible for antagonizing
he deleterious effects of extracorpuscular hemoglobin dur-
ng episodes of intraplaque hemorrhage (30). Two common
lleles exist at the haptoglobin locus (1 and 2), and the
aptoglobin-2 allele is associated with decreased antioxida-
ive and anti-inflammatory activity of haptoglobin, resulting
n increased vascular damage. These effects were demonstrated
n vivo, showing increased iron deposition, lipid peroxidation,
nd macrophage accumulation in atherosclerotic plaques from
polipoprotein E knockout haptoglobin-2 transgenic mice (31)
Fig. 3).
maging of Atherothrombosis
nvasive techniques. Intravascular ultrasound (IVUS)
onsolidated during 2006 as a powerful tool for the evalu-
tion of coronary atherosclerotic burden, which cannot be
eliably predicted by luminal angiography or assessment of
Figure 3 Plaque Inflammation and Haptoglobin Variants
Color illustrations and bar graphs comparing macrophage content in atherosclerotardiovascular risk factors alone (32). Serial IVUS evalua-
ions showed that progression of disease is associated with
ccentric remodeling that is not limited by plaque extent,
hereas plaque stabilization and regression are accompanied
y constrictive remodeling (33). A study evaluating the 3
ain coronary arteries with IVUS and radiofrequency data
nalysis (virtual histology) in patients referred for interven-
ion showed that patients with at least 1 plaque rupture
resented a larger plaque burden despite a similar lumen
ross-sectional area (34). In addition, as discussed in the
ection Therapy, IVUS studies provided important mecha-
istic insights of the beneficial effects of antiatherosclerotic
reatments (Fig. 4).
Intracoronary angioscopy was evaluated as a potential tool
or prognostic stratification. In a prospective evaluation
ncluding500 patients, the presence and number of yellow
ues of apolipoprotein E knockout mice with the
Figure 4 LDL Cholesterol and Coronary Disease Progression
Relationship between plasmatic low-density lipoprotein (LDL) cholesterol levels
and progression/regression of disease (quantified as median change in per-
cent atheroma volume) as derived from several intravascular ultrasound trials.
Reproduced from Nissen et al. (65). (JAMA, April 5, 2006, Vol. 295, page
1563; Copyright © [2006], American Medical Association. All rights reserved.)ic plaq
haptoglobin (Hp) 1-1 or Hp 2-2 genotype. Increased macrophage infiltration (black arrows) is noted in the Hp 2-2 plaques. Adapted with permission from Levy et al. (31).
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April 24, 2007:1740–9 Year in Atherothrombosislaques (a feature suggestive of large lipid cores and thin
brous caps) was independently associated with future risk
f acute coronary syndromes (35).
omputed tomography. New reference values of coronary
alcium distribution in subjects without clinical cardiovas-
ular disease (or treated diabetes) became available from the
ESA (Multi-Ethnic Study of Atherosclerosis) trial, al-
owing for improved interpretation of the degree of coronary
alcification according not only to age and gender, but also
o ethnicity (36). Data from the same cohort suggested that
he prevalence of hyperlipidemia requiring drug therapy is
30%; however, in approximately 45% of the remaining
ubjects there was detectable coronary calcification, and in
% the score was 400, indicative of high cardiovascular
isk (37). Similar observations prompted a provocative
xpert consensus statement proposing a new paradigm in
rimary prevention, guided by universal noninvasive athero-
clerosis imaging (specifically carotid intima-media thick-
ess and coronary calcium scoring) in all asymptomatic
ntermediate-risk subjects as defined by age and gender (38).
Garcia et al. (39) reported the first multicenter compar-
son of 16-slice multidetector computed tomography
MDCT) and invasive coronary angiography in 187 pa-
ients, using quantitative determination of stenosis degree.
fter including all nonevaluable segments (29%) in the
nalysis as positive, the per-patient sensitivity, specificity,
ositive predictive value, and negative predictive value for
he detection of 50% luminal diameter narrowing were
8%, 54%, 50%, and 99%, respectively. Subsequently, a
eta-analysis of 29 studies (2,000 patients) comparing
16-slice MDCT and invasive angiography reported
ooled values of 96%, 74%, 83%, and 94% for the same
arameters. These results were reached after exclusion from
he analysis of 4.2% unassessable segments, and inclusion of
.4% nonevaluable segments categorized at the discretion of
he investigators. A trend was noted for a small improve-
ent in accuracy for 64-slice scanners. These results under-
core a moderate specificity and a high negative predictive
alue, with a potential role in patients with low to interme-
iate disease prevalence (40).
ardiac magnetic resonance. Another meta-analysis of 50
tudies of coronary angiography with MDCT (4- and
6-slice) or magnetic resonance imaging (MRI) showed
uperior performance of MDCT at the present time (Fig. 5)
41). Additional relevant information that can be obtained
ith MRI includes delayed enhancement. To evaluate the
rognostic implications of subclinical myocardial damage,
he presence of newly found myocardial scarring was the
trongest predictor of cardiac events and mortality in one
tudy, even after adjusting for risk factors, coronary anat-
my, ejection fraction, or wall motion abnormalities (42).
oreover, the extent of MRI-determined peri-infarct zone
as identified as a novel independent predictor of cardio-
ascular mortality (43). In addition, a MESA substudy
howed negative correlations between atherosclerosis extent
nd both regional systolic and diastolic function using MRI magging, suggesting an early negative impact of subclinical
therosclerosis before overt myocardial failure (44).
oninvasive visualization of the vessel wall. Data from
he Dallas Heart Study showed that quantification of aortic
laque burden with MRI detected subclinical atherosclero-
is more often than calcium scoring (9). Another investiga-
ion described an association of complex plaques in the
bdominal aorta and the coronary tree, consistent with
ystemic atherosclerosis instability (45). Multicontrast,
igh-resolution MRI was used in a prospective evaluation in
54 patients with asymptomatic 50% to 79% carotid steno-
is. Several plaque features (intraplaque hemorrhage, large
ecrotic core, maximum wall thickness, and particularly a
hin or ruptured fibrous cap) were identified as strong
redictors of subsequent ipsilateral cerebrovascular events
46). In addition, measurements derived from kinetic mod-
ling of the first pass of contrast through carotid plaques
howed strong correlations with macrophage content and
eovascularization degree, supporting a possible role for the
etection of inflammatory activity and vulnerability (47).
nderscoring the importance of merging different imaging
odalities, Davies et al. (48) combined MRI for plaque
isualization and 18fluorodeoxyglucose positron emission
omography for the detection of inflammatory activity, and
uggested a potential use in the identification of culprit
esions (Fig. 6).
olecular imaging. Through the visualization of specific
olecular processes with known roles in atherosclerosis
evelopment and progression, molecular imaging continued
o develop as a tool for the evaluation of disease activity.
ovel imaging probes were able to detect expression of
ascular adhesion molecule-1 or the action of matrix
Figure 5 Diagnostic Performance of Coronary
Angiography With MRI and MDCT
Weighted sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of coronary angiography with multidetector computed
tomography (MDCT) and magnetic resonance imaging (MRI) after inclusion of
unassessable segments. Data from Schuijf et al. (41).etalloproteinases in vivo (49,50). Moreover, the possibil-
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Year in Atherothrombosis April 24, 2007:1740–9ty of using synthetic high-affinity molecular agents as
arriers for therapeutic agents was also explored. The role of
laque neovascularization in atherogenesis and vulnerability
as reviewed in detail in 2006 (51), and a nanoparticle targeted
o v3 integrins was coupled with fumagillin, an antiangio-
enic agent, in an attempt to decrease plaque neovasculature in
n experimental model of atherosclerosis. The drug successfully
educed the amount of neovessels (as confirmed by histology),
nd these actions could be tracked in vivo with MRI (52).
herapy
isk factor management. Several trials evaluated the ef-
ects of lifestyle changes on cardiovascular risk. In a large
ohort of postmenopausal women, a low-fat diet had
odest effects on cardiovascular risk factors and failed to
ecrease events after an 8-year follow-up (53). On the other
and, a smaller trial in high-risk patients that compared a
ow-fat diet with a Mediterranean diet showed significantly
arger reductions in risk factors with the latter (54). Aside
rom the well-known benefits of exercise, high levels of
nergy expenditure during daily activities were prospectively
Figure 6 Combined PET and MRI Detection of Plaque Inflamma
Transaxial cervical images obtained with high-resolution magnetic resonance imag
fused images (FUSED) in a patient with transient right visual disturbance. (Row A)
internal carotid artery (green arrow), which only shows mild radiotracer uptake on
MRI shows the vertebral arteries (yellow arrows), whereas the FDG-PET and fused
that could be the cause of the patient’s symptoms. Reproduced with permission fssociated with increased survival in a cohort of older adults w55). Another study in a large prospective cohort of 40- to
5-year-old men free of disease (n 42,847) estimated that
60% of primary coronary events could be prevented by
doption of a healthy lifestyle (defined as regular exercise,
bsence of smoking, controlled weight, moderate alcohol
onsumption, and a healthy diet) (56). Several trials evalu-
ted the efficacy of varenicline, a novel partial agonist of the
42 nicotinic acetylcholine receptor, for smoking cessa-
ion. After a 12-week period of therapy, the rates in
ontinuous smoking absence at 1 year were significantly
igher for varenicline (23%) than with bupropion (14.6%)
r placebo (10.3%) (57). The cannabinoid-1 receptor
locker antagonist rimonabant for weight loss in obese
nd overweight patients caused significant weight loss
nd favorable effects in cardiometabolic risk factors in the
IO–NA (Rimonabant In Obesity–North America) trial.
onetheless, these benefits were lost after interruption of
he drug (58).
Updated guidelines for secondary prevention of athero-
hrombotic events were released in 2006 (59). However,
ack of compliance with prescribed therapy remains a
MRI), 18fluorodeoxyglucose (FDG) positron emission tomography (PET), and
agnetic resonance imaging (MRI) shows a large stenotic plaque in the right
G-PET and fused images (blue and red arrows). (Row B) At a different position,
s show a highly inflamed right vertebral artery plaque (white and black arrows)
vies et al. (48).tion
ing (HR
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rom Daidespread problem. In this regard, a study suggested cost-
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April 24, 2007:1740–9 Year in Atherothrombosisffectiveness of fixed combinations of drugs in 1 single pill
polypill) both in primary and in secondary prevention (60).
Some studies evaluated therapy targeted to novel cardiac
isk factors. Despite prior evidence of an independent
elation between homocysteine and cardiovascular disease,
arge randomized placebo-controlled trials failed to show
enefits of homocysteine lowering with folic acid and
itamin B6/B12 supplements, and in fact suggested a trend
or a detrimental effect (61).
ipid therapy. Several studies addressed the protective
ffects of high-intensity statin treatment. Meta-analyses of
studies (n  27,548) of stable disease (TNT [Treating to
ew Targets] and IDEAL [Incremental Decrease in End
oints Through Aggressive Lipid Lowering]) or acute
oronary syndromes (A-to-Z [Aggrastat to Zocor] and
ROVE IT–TIMI-22 [PRavastatin Or atorVastatin
valuation and Infection Therapy–Thrombolysis In
yocardial Infarction]) showed a significant decrease not
Figure 7 Coronary Atheroma Regression Associated With High-
(Top) Baseline and follow-up intravascular ultrasound images of a single coronary
superimposed on the same cross sections, showing the reduction in atheroma are
(65). (JAMA, April 5, 2006, Vol. 295, page 1563; Copyright © [2006], American Mnly in the incidence of coronary death or myocardial snfarction (62), but also in development of heart failure,
ndependent of recurrent infarct (63). Similarly, intensive
tatin therapy early after an acute coronary syndrome was
ssociated with clinical benefits that became evident after
to 12 months (64). In the ASTEROID (A Study to
valuate the Effect of Rosuvastatin on Intravascular
ltrasound-Derived Coronary Atheroma Burden) trial
65), aggressive therapy with rosuvastatin 40 mg/day led
o an average 53% low-density lipoprotein (LDL) cho-
esterol reduction, 15% high-density lipoprotein (HDL)
holesterol increase, and absolute regression of atheroma
olume as shown by IVUS (Fig. 7). Finally, the SPARCL
Stroke Prevention by Aggressive Reduction in Choles-
erol Levels) Trial tested atorvastatin 80 mg/day in 4,731
atients with a recent stroke or transitory ischemic attack,
DL  100 to 190 mg/dl, and no known coronary disease.
fter a median of 5 years, atorvastatin was associated not
nly with a 16% relative risk reduction for recurrent
sity Statin Therapy
section after 24 months of rosuvastatin treatment. (Bottom) Measurements
 external elastic membrane. Reproduced with permission from Nissen et al.
Association. All rights reserved.)Inten
cross
a. EEM
edicaltroke (11.2% vs. 13.1%, p  0.03) in comparison with
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Year in Atherothrombosis April 24, 2007:1740–9lacebo, but also with a decrease in the rate of coronary
vents (66).
Another relevant aspect of lipid therapy was HDL. A
ost hoc analysis of the BIP (Bezafibrate Infarction Preven-
ion) trial suggested that the degree of HDL elevation
btained with bezafibrate, a peroxisome proliferator-
ctivated receptor (PPAR)- agonist, was independently
ssociated with reduced cardiac mortality (67). In addition,
study evaluating the effects of fenofibrate on experimental
therosclerosis with MRI showed a 36% increase in plasma
DL concentration and plaque regression (68). These
avorable effects may be attributable not only to HDL
ugmentation but also to other antiatherogenic properties of
PAR agonists (see subsequent text). As a novel antiathero-
enic mechanism, HDL was shown to enhance EPC
ecruitment into damaged endothelium (69). Despite these
otential benefits of augmenting HDL levels, a phase III
linical trial using the cholesterylester transfer protein in-
ibitor torcetrapib was prematurely stopped due to in-
reased mortality in the torcetrapib-atorvastatin arm in
omparison with atorvastatin alone (70). Alternative HDL-
aising therapies in development include liver X receptor
gonists, recently proven to enhance reverse cholesterol
ransport (71), and oral HDL mimetic peptides (72).
Other tested therapies included pactimibe, a potentially
ntiatherogenic acyl-coenzyme A:cholesterol acyltransferase
ACAT) inhibitor that could enhance reverse cholesterol
ransport. In the ACTIVATE (ACAT Intravascular Ath-
rosclerosis Treatment Evaluation) trial (73), pactimibe
ailed to reduce total IVUS-determined coronary atheroma
olume and seemed to be actually proatherogenic. Also, a
reliminary dose-escalation study in healthy volunteers test-
ng an antisense oligonucleotide with the ability to inhibit
polipoprotein B synthesis reported 35% reductions in LDL
holesterol (74).
ntithrombotic therapy. There was increasing concern
egarding the not uncommon resistance to antiplatelet
gents. A potential contributor to aspirin resistance is
esidual arachidonic acid activity, through a cyclooxygenase
COX)-independent mechanism, causing platelet activation
espite treatment with aspirin (75). In the case of clopi-
ogrel resistance, prasugrel, a more potent thienopyridine,
ummary of Outcomes in the CHARISMA Trial
Table 1 Summary of Outcomes in the CHARISMA Trial
Aspirin  Clopidogrel
(n  7,802)
Primary efficacy end point 6.8%
Principal secondary efficacy end point 16.7%
Nonfatal stroke 1.9%
Hospitalization 11.1%
Severe bleeding 1.7%
Moderate bleeding 2.1%
he primary efficacy end point includes cardiovascular death, myocardial infarction, and stroke. The
ransient ischemic attack or revascularization). Individual end points with statistically significant d
CHARISMA  Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Managemay be a promising alternative according to preliminary Ttudies (76). Regarding the deleterious effects of COX-2
nhibition, initial experimental evidence suggested that
ome may be counteracted by low-dose clopidogrel (77). In
ddition, increased cardiovascular risk was shown not only
ith selective COX-2 inhibitors but also with frequent use
f nonselective nonsteroidal anti-inflammatory drugs, in-
luding acetaminophen (78). These findings likely reflect
he complex influence on atherosclerosis of COX-1 and -2
alanced activities.
The highlight of the year in terms of antithrombotic
herapy came from the CHARISMA (Clopidogrel for High
therothrombotic Risk and Ischemic Stabilization, Man-
gement, and Avoidance) trial, which randomized 15,603
ymptomatic (defined as documented coronary, cerebrovas-
ular, or peripheral arterial disease) and asymptomatic
atients with multiple risk factors (a significant percentage
f whom had prior cardiovascular events) to aspirin plus
lopidogrel or aspirin plus placebo. There were no signifi-
ant differences in the rate of the primary composite
utcome, with a marginally significant benefit for the
lopidogrel group in the principal secondary end point, at
he cost of increased risk of moderate bleeding (Table 1).
mportantly, although there was suggestion of a benefit with
lopidogrel in the primary outcome for symptomatic pa-
ients (6.9% vs. 7.9%, p  0.046), the rate of cardiovascular
eath was higher in the asymptomatic group receiving
lopidogrel (3.9% vs. 2.2%, p  0.01) (79). Concordant
ffects of dual antiaggregation were reported in the ESPRIT
Estrogen in the Prevention of Reinfarction Trial), which
andomized patients with minor ischemic stroke or transi-
ory ischemic attack in the past 6 months to aspirin alone or
spirin plus dipyridamole. The results of the trial and those
f a meta-analysis of prior studies published simultaneously
howed a significant reduction of the combination of vas-
ular death, infarction, or recurrent stroke (80). Finally,
ovel approaches for antiplatelet therapy included dual antag-
nism of platelet receptors for thrombin (81), or oral, reversible
denosine diphosphate receptor blockers that, unlike thieno-
yridines, do not require metabolic activation (82).
dditional therapies. A meta-analysis of 3 large trials
HOPE, PEACE [Prevention of Events With Angiotensin-
onverting Enzyme Inhibition], and EUROPA [European
spirin  Placebo
(n  7,801)
Relative Risk
(95% Confidence Intervals) p Value
7.3% 0.93 (0.83–1.05) 0.22
17.9% 0.92 (0.86–0.99) 0.04
2.4% 0.79 (0.64–0.98) 0.03
12.3% 0.90 (0.82–0.98) 0.02
1.3% 1.25 (0.97–1.61) 0.09
1.3% 1.62 (1.27–2.08) 0.001
dary efficacy end point includes the same events plus hospitalization (because of unstable angina,
ce between the groups are also shown. Data from Bhatt et al. (79).
d Avoidance.A
seconrial on Reduction of Cardiac Events With Perindopril in
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ngiotensin-converting enzyme inhibitors in patients with
stablished atherosclerosis but without heart failure or left
entricular dysfunction reported an 18% relative risk de-
rease in the incidence of cardiovascular death, infarction, or
troke (83).
Finally, important information regarding the manage-
ent of diabetic atherosclerosis became available in the last
ear. In the PROactive (PROspective pioglitAzone Clinical
rial In macroVascular Events) trial, 5,238 patients with
ype 2 diabetes and evidence of macrovascular disease were
rospectively randomized to pioglitazone (a PPAR- acti-
ator) or placebo. After an average follow-up of 34 months,
ioglitazone was associated with a significant reduction in
he composite end point of death, nonfatal myocardial
nfarction, and stroke (hazard ratio 0.84, p  0.027) (84).
oreover, novel applications of thiazolidinediones in non-
iabetic patients are being explored, and pioglitazone was
hown to increase HDL, improve endothelial function, and
educe inflammatory markers (85).
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